| Literature DB >> 11714391 |
T Dörner1, S Kaschner, A Hansen, A Pruss, P E Lipsky.
Abstract
To assess the impact of somatic hypermutation and selective influences on the Vlambda light chain repertoire in systemic lupus erythematosus (SLE), the frequency and pattern of mutations were analyzed in individual CD19+ B cells from a patient with previously undiagnosed SLE. The mutational frequency of nonproductive and productive rearrangements in the SLE patient was greater (3.1 x 10(-2) vs 3.4 x 10(-2), respectively) than that in normal B cells (1.2 x 10(-2) vs 2.0 x 10(-2), both P < 0.001). The frequencies of mutated rearrangements in both the nonproductive and productive repertoires were significantly higher in the patient with SLE than in normal subjects. Notably, there were no differences in the ratio of replacement to silent (R/S) mutations in the productive and nonproductive repertoires of the SLE patient, whereas the R/S ratio in the framework regions of productive rearrangements of normal subjects was reduced, consistent with active elimination of replacement mutations in this region. The pattern of mutations was abnormal in the SLE patient, with a significant increase in the frequency of G mutations in both the productive and nonproductive repertoires. As in normal subjects, however, mutations were found frequently in specific nucleotide motifs, the RGYW/WRCY sequences, accounting for 34% (nonproductive) and 46% (productive) of all mutations. These data are most consistent with the conclusion that in this SLE patient, the mutational activity was markedly greater than in normal subjects and exhibited some abnormal features. In addition, there was decreased subsequent positive or negative selection of mutations. The enhanced and abnormal mutational activity along with disturbances in selection may play a role in the emergence of autoreactivity in this patient with SLE.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11714391 PMCID: PMC64848 DOI: 10.1186/ar329
Source DB: PubMed Journal: Arthritis Res ISSN: 1465-9905
Mutational frequency of the nonproductive and productive Vλ repertoires of the patient with systemic lupus erythematosus (SLE) and normal subjects
| Patient with SLE | Normal subjects | |||||
| Nonproductive | Productive | Χ2 | Nonproductive | Productive | Χ2 | |
| Number of Vλ nucleotides | 16679 | 28496 | 12679 | 39225 | 0.001 | |
| Number of Vλ nucleotides in | 13194 | 23819 | 6339 | 21821 | 0.001 | |
| mutated rearrangements | ||||||
| Number of mutations | 412 | 807 | 76 | 440 | ||
| Mutational frequency of all | 2.5 | 2.8 | 0.022 | 0.60 | 1.12 | 0.001 |
| VλJλ gene rearrangements (%) | ||||||
| Mutational frequency of mutated | 3.1 | 3.4 | NS | 1.19 | 2.02 | 0.001 |
| VλJλ gene rearrangements (%) | ||||||
J = joining [region]; NS = not significant; V = variable [region].
Ratio (R/S) of replacement mutations to silent mutations in regions of Vλ in a patient with SLE and in normal human subjects
| Patient with SLE | Normal subjects* | |||
| Region of Vλ | Nonproductive rearrangements | Productive rearrangements | Nonproductive rearrangements | Productive rearrangements |
| FR1 | 1.0b (4/4) | 7.3b (29/4) | 0.0 (0) | 1.8 (9/5) |
| CDR1 | 7.8 (47/6) | 6.3a (113/18) | 3.0 (12/4) | 3.9a (55/14) |
| FR2 | 3.1 (49/16) | 2.5 (95/38) | 0.0b (11/0) | 1.8b (51/29) |
| CDR2 | 8.2 (41/5) | 10.9 (76/7) | 10.0 (10/1) | 4.8 (48/10) |
| FR3 | 2.9 (112/39) | 3.1 (185/59) | 4.0 (12/3) | 2.4 (66/28) |
| CDR3 | 8.7 (52/6) | 8.0a (96/12) | 3.0 (15/5) | 3.7a (81/22) |
| FRs | 2.8 (165/59) | 3.1a (309/101) | 7.7b (23/3) | 2.0a,b (126/62) |
| CDRs | 8.2 (140/17) | 7.7a (285/37) | 3.7 (37/10) | 4.0a (184/46) |
| Total | 4.0 (305/76) | 4.3a (594/138) | 4.6 (60/13) | 2.9a (310/108) |
*The data for normal subjects have been published elsewhere [23]. aSignificant difference between ratio in SLE patient and normal subjects; P < 0.05 (Χ2 test). bSignificant difference between ratio in nonproductive and productive rearrangements; P < 0.05 (Χ2 test). CDR = complementarity-determining region; FR = framework region.
Figure 1Frequency of mutated base pairs of the nonproductive and productive Vλ gene repertoires of the patient with systemic lupus erythematosus in comparison with those found in normal subjects. NHS = normal human subjects; SLE = systemic lupus erythematosus.
Nature of base-pair substitutions
| Substitution to | |||||||||
| Nonproductive Vλ rearrangements | Productive Vλ rearrangements | ||||||||
| Region of | |||||||||
| substitution | Substitution from | T | C | A | G | T | C | A | G |
| CDR | T | - | 2.9 | 1.0 | 0.5 | - | 1.9 | 1.4 | 1.1 |
| C | 2.9 | - | 0.2 | 3.4 | 3.0 | - | 1.1 | 1.3 | |
| A | 5.8 | 2.4 | - | 4.1 | 7.0 | 3.1 | - | 6.7 | |
| G | 7.8 | 5.3 | 5.8b | - | 6.1 | 4.7 | 6.9b | - | |
| FR | T | - | 2.6 | 1.7 | 3.1 | - | 2.9 | 1.7 | 2.0 |
| C | 7.5 | - | 3.4 | 4.1 | 6.8 | - | 2.0 | 4.5 | |
| A | 4.2 | 2.7 | - | 3.9 | 5.0 | 2.6 | - | 6.3 | |
| G | 5.3 | 3.4 | 15.8b | - | 5.3 | 4.8 | 11.7b | - | |
| Total | T | - | 5.5 | 2.7 | 3.6 | - | 4.8 | 3.1 | 3.1 |
| C | 10.4 | - | 3.6 | 7.5 | 9.8 | - | 3.1 | 5.8 | |
| A | 10.0 | 5.1 | - | 8.0a | 12.0 | 5.7 | - | 13.0a | |
| G | 13.1 | 8.7 | 21.6 | - | 11.4 | 9.5 | 18.6 | - | |
aComparison of nonproductive and productive Vλ genes; P < 0.05 (Χ2 test). bComparison between mutations in the CDRs and FRs; P < 0.005 (Χ2 test). CDR = complementarity-determining region; FR = framework region.
Supplementary Figure 1Distribution of mutational events within the nonproductive (left panel) and productive (right panel) Vλ rearrangements in CD19+ B cells from a patient with systemic lupus erythematosus. The percentages of mutated codon positions are given and the mutational hot spots are indicated. Mutational hot spots were determined as described in Supplementary materials and methods. Codons used only by a few rearrangements were not considered in the diagram. CDR = complementarity-determining region.
Supplementary Figure 2Mutational frequencies of RGYW sequences and those of their inverse repeats, WRCY, in the nonproductive and productive Vλ gene repertoires of the patient with SLE and in normal control subjects. SLE = systemic lupus erythematosus.